Altana submits roflumilast in Europe
This article was originally published in Pharmaceutical Approvals Monthly
Daxas (roflumilast) marketing authorization application has been submitted to the European Medicines Evaluation Agency, Altana announces Feb. 13. In the U.S., the oral, once-daily, selective phosphodiesterase-4 inhibitor is in Phase III for treatment of chronic obstructive pulmonary disease and asthma with development partner Pfizer...
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Following Perrigo’s announcement of a recall of its generic albuterol inhalers in the US, the FDA has commented on the move and has revealed that thousands of complaints have been received over the clogging problem.